Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma
Alexandra Drakaki, Preet K. Dhillon, Heather A. Wakelee, Jane Yuet Ching Hui, Jinjoo Shim, Matthew Kent, Viraj Degaonkar, Tien Hoang, Virginia McNally, Patricia Luhn, Ralf Gutzmer
Abstract
= .0012). bCS use was associated with shorter OS (not significant for aMel) and TTNT in adjusted multivariable analyses, and clinical outcomes were not explained by prior CS use or other measured confounders. These findings suggest a potential association between bCS use and decreased CPI effectiveness, warranting further investigation.
Topics & Concepts
MedicineSystemic therapyOncologyInternal medicineImmunotherapyMelanomaImmune checkpointImmune systemCancerImmunologyCancer researchBreast cancerCancer Immunotherapy and BiomarkersBladder and Urothelial Cancer TreatmentsCancer, Stress, Anesthesia, and Immune Response